Myelomastocytic leukemia with aberrant CD25 expression: case report and review of the literature

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):e173-7. doi: 10.1016/j.clml.2014.06.003. Epub 2014 Jun 10.

Authors

Amy Rich¹, Jinlan Sun¹, Abdulrahman S Aldayel¹, C Cameron Yin¹, L Jeffrey Medeiros¹, Sergej Konoplev²

Affiliations

¹ Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX.
² Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: [email protected].

PMID: 25022599
DOI: 10.1016/j.clml.2014.06.003

No abstract available

Keywords: AML; Mast cell differentiation; Mast cell leukemia; Myelomastocytic overlap syndrome; Systemic mastocytosis.

Publication types

Case Reports
Review

MeSH terms

Adenocarcinoma / surgery
Antigens, Neoplasm / analysis*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biomarkers, Tumor
Bone Marrow / pathology
Brain / pathology
Cerebral Hemorrhage / etiology
Cytarabine / administration & dosage
Fatal Outcome
Humans
Hydroxamic Acids / administration & dosage
Idarubicin / administration & dosage
Interleukin-2 Receptor alpha Subunit / analysis*
Leukemia, Myeloid, Acute / blood
Leukemia, Myeloid, Acute / classification
Leukemia, Myeloid, Acute / diagnosis
Leukemia, Myeloid, Acute / drug therapy
Leukemia, Myeloid, Acute / metabolism*
Leukemic Infiltration
Male
Mast Cells / pathology
Middle Aged
Neoplasms, Second Primary / blood
Neoplasms, Second Primary / diagnosis
Neoplasms, Second Primary / drug therapy
Neoplasms, Second Primary / metabolism*
Neoplastic Stem Cells / pathology
Opportunistic Infections / etiology
Prostatectomy
Prostatic Neoplasms / surgery
Vorinostat

Substances

Antigens, Neoplasm
Biomarkers, Tumor
Hydroxamic Acids
IL2RA protein, human
Interleukin-2 Receptor alpha Subunit
Cytarabine
Vorinostat
Idarubicin